SCHOLAR ROCK HOLDING CORPORATION Net Income (Loss), Per Outstanding Limited Partnership and General Partnership Unit, Basic and Diluted, Net of Tax
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Net Income (Loss), Per Outstanding Limited Partnership and General Partnership Unit, Basic and Diluted, Net of Tax of -$3.70 per share for the 3-month period ending 2017-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Income Statement › Other Income
us-gaap:NetIncomeLossPerOutstandingLimitedPartnershipAndGeneralPartnershipUnitBasicAndDiluted · last filed 2018-11-08
- SCHOLAR ROCK HOLDING CORPORATION net income (loss), per outstanding limited partnership and general partnership unit, basic and diluted, net of tax for the quarter ending 2017-09-30 was -$3.70.
- SCHOLAR ROCK HOLDING CORPORATION net income (loss), per outstanding limited partnership and general partnership unit, basic and diluted, net of tax for the quarter ending 2017-06-30 was -$3.67.
| Period end | Net Income (Loss), Per Outstanding Limited Partnership and General Partnership Unit, Basic and Diluted, Net of Tax 3 month | Net Income (Loss), Per Outstanding Limited Partnership and General Partnership Unit, Basic and Diluted, Net of Tax 6 month | Net Income (Loss), Per Outstanding Limited Partnership and General Partnership Unit, Basic and Diluted, Net of Tax 9 month |
|---|---|---|---|
| 2017-09-30 | -$3.70 10-Q · filed 2018-11-08 | -$10.32 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$3.67 10-Q · filed 2018-08-08 | -$6.62 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |